Benjamin Kaffenberger is a Dermatology physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 359 publications with 4,948 citations (h-index 34); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1328 Dublin Rd Ste 100
Columbus, OH 432151054
Telephone
614-293-1707Provider last certified this registry record 26 Feb 2021.
Clinical trials
- Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
Sponsor: Ohio State University
- Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
Sponsor: Ohio State University
- The Ohio State University Dermatology Biorepository
Sponsor: Ohio State University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Eli Lilly and CompanyProgram year20251 payment
- Eli Lilly and CompanyProgram year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
31.5%Tetracycline-class Drug10.9%Doxycycline Hyclate42%Doxycycline Monohydrate32%Minocycline Hcl27%Part D≥24 patientsLincosamide Antibacterial7%Clindamycin Phosphate77%Clindamycin Hcl23%Part D≥32 patients+ 6 more classes in this area
Dermatology
22.5%Corticosteroid18.2%Triamcinolone Acetonide52%Triamcinolone acetonide44%Fluocinolone Acetonide4%Part D + Part B<11 patientsInterleukin-4 Receptor alpha Antagonist2.3%Dupixent Syringe63%Dupixent Pen37%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
14.9%Calcineurin inhibitor3.4%Tacrolimus59%Cyclosporine41%Part D<11 patientsNucleoside Metabolic Inhibitor3.2%Fluorouracil100%Part D≥43 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- STRIVE: Short-Term Research in Immunology and Virology Experience
Ohio State University
FY2026$106,414T35AI179601 - STRIVE: Short-Term Research in Immunology and Virology Experience
Ohio State University
FY2025$105,170T35AI179601
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
Journal for ImmunoTherapy of Cancer
2024 - Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
Journal of the American Academy of Dermatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Raphael Pollock, MD, PhD
The Ohio State University Wexner Medical Center
John Kissel, MD
The Ohio State University Wexner Medical Center
Douglas Scharre, MD
The Ohio State University Wexner Medical Center
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”